

Mutations in *PIP5K3* Are Associated with François-Neetens Mouchetée Fleck Corneal Dystrophy

Shouling Li,^{1,*} Leila Tiab,^{3,*} Xiaodong Jiao,¹ Francis L. Munier,⁴ Leonidas Zografos,⁴ Béatrice E. Frueh,⁵ Yuri Sergeev,¹ Janine Smith,² Benjamin Rubin,¹ Mario A. Meallet,⁶ Richard K. Forster,⁷ J. Fielding Hejtmancik,¹ and Daniel F. Schorderet^{3,4}

¹Ophthalmic Genetics and Clinical Services Branch and ²Office of the Clinical Director, National Eye Institute, Bethesda, MD; ³Institut de Recherche en Ophthalmologie, Sion, Switzerland; ⁴Jules Gonin Eye Hospital, Lausanne, Switzerland; ⁵Department of Ophthalmology, Inselspital, Bern, Switzerland; ⁶LA County and USC Medical Center/Doheny Eye Institute, Los Angeles; and ⁷Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami

François-Neetens fleck corneal dystrophy (CFD) is a rare, autosomal dominant corneal dystrophy characterized by numerous small white flecks scattered in all layers of the stroma. Linkage analysis localized CFD to a 24-cM (18-Mb) interval of chromosome 2q35 flanked by *D2S2289* and *D2S126* and containing *PIP5K3*. *PIP5K3* is a member of the phosphoinositide 3-kinase family and regulates the sorting and traffic of peripheral endosomes that contain lysosomally directed fluid phase cargo, by controlling the morphogenesis and function of multivesicular bodies. Sequencing analysis disclosed missense, frameshift, and/or protein-truncating mutations in 8 of 10 families with CFD that were studied, including 2256delA, 2274delCT, 2709C→T (R851X), 3120C→T (Q988X), IVS19-1G→C, 3246G→T (E1030X), 3270C→T (R1038X), and 3466A→G (K1103R). The histological and clinical characteristics of patients with CFD are consistent with biochemical studies of *PIP5K3* that indicate a role in endosomal sorting.

Introduction

François-Neetens fleck corneal dystrophy (CFD [MIM 121850]) is an autosomal dominant corneal dystrophy characterized by numerous small white flecks scattered in all layers of the stroma. François and Neetens described this disorder for the first time in 1957, calling it “hérérodystrophie mouchetée” (François and Neetens 1957). Typically, the stroma in between the flecks is clear, and the endothelium, epithelium, Bowman layer, and Descemet membrane are normal. Except for an occasional patient with minor photophobia, patients are usually asymptomatic and have normal vision; the disease is most often found at routine examination. The corneal flecks appear to not progress significantly throughout life (Patten et al. 1976; Akova et al. 1994). In vivo confocal microscopy examination has made the clinical diagnosis more straightforward, with CFD evident by small bright deposits around keratocyte nuclei throughout the stroma.

The flecks in CFD may appear as early as at 2 years of age or even at birth, but generally they are reported

not to progress significantly throughout life. However, individual 15 in family 50003 showed no signs of CFD on slit-lamp examination at age 2 years, but, at age 6 years, it was observed that two stromal lesions in the left eye and one in the right eye had developed (Jiao et al. 2003). Although CFD is thought to be rare, specific incidence figures are difficult to obtain. It has been suggested that, because of its subtle presentation, CFD might be much more common than has been appreciated in the literature (Streeten and Falls 1961; Birndorf and Ginsberg 1972; Patten et al. 1976; Goldberg et al. 1977).

On histological examination, the corneal flecks appear to correspond to abnormal keratocytes swollen with membrane-limited intracytoplasmic vesicles containing complex lipids and acid mucopolysaccharides. There are no extracellular abnormalities (Nicholson et al. 1977; Purcell et al. 1977), and laboratory screening has shown no systemic metabolic abnormalities (Patten et al. 1976). Thus, it was thought that this dystrophy might represent a dominantly inherited metabolic disorder confined to the cornea (Nicholson et al. 1977). CFD was previously mapped to a 27.9-cM region of chromosome 2q35 flanked by *D2S117* and *D2S126*, with the highest LOD scores shown at *D2S2289* ($Z_{\max} = 4.46$; $\theta = 0$), *D2S325* ($Z_{\max} = 3.28$; $\theta = 0$), *D2S317* ($Z_{\max} = 3.1$; $\theta = 0$), *D2S143* ($Z_{\max} = 3.8$; $\theta = 0.03$), and *D2S2382* ($Z_{\max} = 5.0$; $\theta = 0$). Multipoint analysis confirmed linkage to the region between *D2S117* and *D2S126*, with a maximum multipoint

Received March 7, 2005; accepted for publication April 25, 2005; electronically published May 18, 2005.

Address for correspondence and reprints: Dr. Daniel F. Schorderet, Institut de Recherche en Ophthalmologie, Avenue du Grand-Champ sec 64, 1950 Sion, Switzerland. E-mail: daniel.schorderet@iro.vsnnet.ch

* These two authors contributed equally to this work.

© 2005 by The American Society of Human Genetics. All rights reserved. 0002-9297/2005/7701-0006\$15.00

Table 1**PCR Primers for 41 Exons and cDNA of *PIP5K3***

The table is available in its entirety in the online edition of *The American Journal of Human Genetics*.

LOD score of 5.0 located midway between *D2S2289* and *D2S325*. Analysis of CFD in the same families with the assumption of 90% penetrance increased the maximum LOD score to 6.28 at *D2S157* (Jiao et al. 2003).

The present study was performed with 10 families, including the original 4 families studied by Jiao et al. (2003), and refined the linked region to a 24-cM interval flanked by *D2S2289* and *D2S126* and containing ~18 Mb. Sequencing of numerous candidate genes in this region in affected members from 8 of 10 families showed mutations in *PIP5K3*, which encodes a widely expressed 2,089-aa phosphoinositide 3-kinase family member active in post-Golgi vesicular sorting.

Material and Methods

Patients and Clinical Findings

Ten unrelated families of European origin that contain 69 individuals, including 32 affected individuals, 27 unaffected individuals, and 10 unaffected spouses, were enrolled in this study. Families 50001 and 50007 are of mixed European origin (American), family 50002 is of Italian origin, family 50004 is of Yugoslavian origin, and the remaining families are of Swiss origin. Control individuals were of mixed European origin (from the United States, Italy, and Switzerland). The diagnosis of CFD was based on the presence of typical small white flecks throughout the corneal stroma. Both affected and unaffected family members underwent a complete ophthalmological examination. In affected individuals, the corneal epithelium and endothelial layer showed no abnormalities. The corneal stroma showed the presence of typical hyperreflective dots throughout but was otherwise normal. Confocal microscopy findings for family 5005 also showed hyperreflective inclusions associated with the basal nerves (Frueh and Bohnke 1999). Detailed ocular, medical, and family histories were obtained for each available family member. This project was approved by the institutional review board of the National Eye Institute and by the Ethics Committee of the Faculty of Medicine, University of Lausanne. The patients admitted to this study gave their informed consent, and the study adhered to the tenets of the Declaration of Helsinki.

Genotyping and Linkage Analyses

DNA was extracted either directly from blood or from transformed lymphoblastoid cell lines, by use of stan-

dard phenol-chloroform protocols (Smith et al. 1989). Two-point linkage analysis was performed using the FASTLINK version (Schaffer et al. 1994) of MLINK from the LINKAGE program package (Lathrop and Lalouel 1984; Cottingham et al. 1993). Maximum LOD scores were calculated using ILINK. CFD was initially analyzed as a fully penetrant, autosomal dominant trait. The gene frequency of CFD was set at 0.0001, and an equal allele frequency was used for all markers.

Candidate-Gene Analysis

Candidate genes were chosen in the 24-cM CFD-linked interval flanked by *D2S2289* and *D2S126* on chromosome 2q35, estimated to contain >300 genes or potential genes. To confirm that the candidate genes are expressed in the human cornea, human corneal total RNA was extracted with an RNeasy Fibrous Tissue Mini kit (QIAGEN), corneal cDNA was made using RT-PCR with the use of SuperScript™ III First-Strand Synthesis System (Invitrogen), and direct PCR amplification of the cDNA was performed. Expression of *PIP5K3* was tested by PCR analysis of corneal cDNA with the use of exon 1 forward and exon 3 reverse primers (table 1).

Denaturing High-Pressure Liquid Chromatography (DHPLC) and Sequence Analysis

Coding exons and adjacent intronic sequences of *PIP5K3* were amplified from genomic DNA by use of the primers shown in table 1. PCR amplification of each of the 41 exons was performed in 20- μ l reactions involving 2.5 U of AmpliTaq Gold (ABI), 2 μ l of 10 \times AmpliTaq Gold Buffer, 1.9 mM MgCl₂, 0.25 mM dNTPs, 0.25 mM of primers, and 40 g of genomic DNA. PCR cycling conditions consisted of an initial 10-min denaturation step at 95°C for 5 min; 32 cycles at 94°C for 40 s, 55°C for 30 s (61°C for exon 19b), and 72°C for 40 s; and a final elongation step at 72°C for 7 min. PCR products were screened by DHPLC on a WAVE system (Transgenomics). Buffer A contained 0.1 M triethylammonium acetate (TEAA [Transgenomics]). Buffer B contained 0.1 M TEAA and 25% acetonitrile, HPLC grade (Sigma-Aldrich). The flow rate was set at 0.9 ml/min, and the buffer B gradient increased by 2% per min for 4 min. The optimum temperature was determined for each DNA fragment by Wavemaker software (Transgenomics). When multiple melting domains were established, each domain was analyzed at the appropriate temperature. Initial buffer B concentrations

Table 2**Conditions for DHPLC of *PIP5K3* Exons**

The table is available in its entirety in the online edition of *The American Journal of Human Genetics*.




Figure 1 Slit-lamp image (A) and confocal microscopy image (B) of the cornea in a patient with CFD

and temperatures for each fragment are listed in table 2. PCR products were purified using Millipore Montage PCR μ 96 plates or QIAquick PCR purification kits. The PCR templates were sequenced using ABI Dye Terminator, version 1 or 3, in a final reaction volume of 10 μ l. Products of the sequencing reactions were purified using the Edge Biosystems Performa TM DTR gel-filtration system and were run on a 3100 ABI genetic analyzer. Sequences were aligned using the Seqman program of the DNASTAR package (DNASTAR) or Chromas, version 2.23 (Technelysium). The reference genomic sequence is available from NCBI (accession number NM_015040).

Protein Analysis

Structural motifs of the lipoprotein lipid attachment site were localized in the phosphatidylinositol-4-phosphate 5-kinase type III sequence (PIP5K3) by use of PROSITE. The search for spectrin sequence repeats was performed using rapid automatic detection and alignment of repeats (RADAR), and a search for structural motifs was performed using the simple modular architecture research tool (SMART), the Superfamily 1.65 HMM library and genome assignment service, the NIH homology alert service Whales, and the protein families database (PFAM) (see Web Resources). Sequence alignment was performed using the GCG-Lite+ ClustalW 1.74 multiple sequence alignment program (see Web Resources).

The chaperone-like domain structure of PIP5K3 was derived by homology modeling, with the crystal coor-

dinate of protein database (PDB) file 1a6d as the structural template (Abola et al. 1987). For each model, amino acid sequences were aligned using the method of Needleman and Wunsch (1970). The three-dimensional structure was built using the program Look, version 3.5.2 (Lee and Subbiah 1991; Lee 1994), followed by 500 cycles of nonbound energy minimization. The conformation of mutant proteins was refined by 500 cycles of self-consistent ensemble optimization (Lee 1994). The geometry of the predicted structures was tested with the Procheck program (Laskowski et al. 1993).

Results

Patient Ascertainment

Individuals were diagnosed as affected on the basis of the typical appearance of corneal flecks on slit-lamp examination and, in some individuals, in vivo confocal microscopy (fig. 1). Of the 10 families investigated here, 4 (families 50001, 50002, 50003, and 50004) were previously studied by Jiao et al. (2003) and are described more fully in that study. Additional individuals and families 50005, 50006, 50008, 50009, and 50010 showed classical CFD and were asymptomatic, whereas affected individuals from family 50007 showed photophobia, which was severe enough in individual 5 (see pedigree in fig. 2) to result in blepharospasm and facial spasm, requiring multiple botulinum toxin injections to control the spasms. Family 50005 and one affected individual from family 50006 were reported elsewhere (Frueh and Bohnke 1999).




Figure 2 Pedigrees of families, with haplotypes for markers in the CFD region of chromosome 2 in the families used for linkage analysis. Blackened bars indicate the risk haplotype inherited by all affected individuals in a family.




Figure 3 Sequence analysis for representative affected individuals from families with CF. HTZ = heterozygous.

Linkage Analysis

Two-point linkage analysis suggested that the CFD locus is linked to a 12-cM region flanked by *D2S2289* and *D2S143* (table 3). This region includes markers *D2S325* ($Z_{\max} = 4.64$; $\theta = 0$) and *D2S317* ($Z_{\max} = 3.67$; $\theta = 0$). Significant LOD scores were also seen with other markers in the region, including *D2S2289* ($Z_{\max} = 4.7$; $\theta = 0.03$), *D2S143* ($Z_{\max} = 4.83$; $\theta = 0.05$), *D2S2382* ($Z_{\max} = 5.27$; $\theta = 0.3$), and *D2S2249* ($Z_{\max} = 4.54$; $\theta = 0.04$), although these markers showed obligate recombinants.

Haplotype analysis confirmed the critical interval (fig. 2). A recombination event in affected individual 7 of family 50007 set the centromeric boundary at *D2S2289*, and other centromeric obligate recombination events took place between *D2S117* and *D2S311* in individual 10 of family 50001, individual 16 of family 50003, and individual 7 of family 50004. Telomeric obligate recombination events took place between *D2S126* and *D2S396* in affected individuals 12 and 16 of family 50003, and the recombination in affected individual 14 of family 50003 set the telomeric boundary at *D2S126*. In addition, unaffected individual 9 of family 50001 showed a recombination event at *D2S2359*, and unaffected individual 7 of family 50001 showed an obligate recombination at *D2S143*. Thus, the CFD locus is linked to chromosome 2 between *D2S2289* and *D2S126*, and—on the basis of recombination events in unaffected individuals in whom the gene might not, in fact, be penetrant—the locus is probably between *D2S2289* and *D2S143*. In family 50003, unaffected individuals 3 and 18 share part of the risk haplotype, although individuals 1, 2, and 4 (through whom individuals 3 and 18 are connected to the affected individuals in this family) were not available for genotyping and examination.

DHPLC and Mutation Analysis



The interval contains *PIP5K3*, which has 41 coding exons spanning >89 kb and encodes a 2,098-aa protein. PCR amplification and DHPLC, followed by direct sequencing of the putative exons and intron-exon boundaries, showed mutations in 8 of 10 families studied (fig. 3). Mutations were confirmed in all available affected family members.

Screening of exon 16 revealed two significant sequence variations. Family 50001 showed mutation 2256delA, which causes a shift of the reading frame and the generation of an early stop codon after 6 aa, removing the final 1,392 aa. Family 50004 showed 2274delCT, which also causes a shift of the ORF and an early truncation after 5 aa. Five other families exhibit mutations in exon 19. Nonsense mutation 2962C→T (Q988X) was observed in family 50003; 2709C→T (R851X) in family 50005; 3246G→T (E1030X) in family 50008; and 3270C→T (R1038X) in family 50009. Family 50010 displays the only missense mutation observed to date. Nucleotide A at position 3466 was mutated to G, changing the lysine codon at position 1103 to arginine. In family 50007, the splice-acceptor site of exon 20 shows an IVS19-1 G→C transversion. This is predicted to cause skipping of exon 20, with a resultant frame shift and an early truncation after 10 additional amino acids. All these mutations were observed in a heterozygous state and were not observed in 100 control individuals (200 control individuals for mutation K1103R) of similar (European) ethnic background. In two families, 50002 and 50006, the complete screening of the coding regions of *PIP5K3* revealed neither point mutations nor small insertions and deletions. In family 50002, a single base insertion (IVS15-82insA) was observed in intron 15, as well as the 13-bp deletion IVS15+11→24. Both these

Table 3

Two-Point Linkage Results for Markers in the CFD Region of Chromosome 2q35

MARKER	POSITION		LOD SCORE AT $\theta =$								Z_{\max}	$\hat{\theta}$
	cM	Mb	0	.01	.05	0.1	.02	.03	.04			
<i>D2S364</i>	192.90	182.86	∞	-1.32	1.14	1.89	2.05	1.57	.82	2.05	.2	
<i>D2S117</i>	201.40	195.44	∞	-3.90	-1.22	-.21	.48	.53	.30	.53	.3	
<i>D2S311</i>	203.10	197.39	∞	1.75	2.87	3.04	2.60	1.75	.75	3	.07	
<i>D2S2289</i>	205.40	203.49	∞	4.42	4.74	4.53	3.66	2.48	1.16	4.7	.03	
<i>D2S325</i>	210.90	208.10	4.64	4.60	4.36	3.99	3.11	2.08	.98	4.64	0	
<i>D2S157</i>	212.60	211.03	1.32	1.55	1.91	2.00	1.79	1.31	.69	2	.1	
<i>D2S317</i>	215.10	213.33	3.67	3.61	3.38	3.05	2.29	1.45	.63	3.67	0	
<i>D2S143</i>	217.00	214.70	∞	3.87	4.83	4.82	4.02	2.75	1.25	4.83	.05	
<i>D2S2382</i>	220.70	216.87	∞	5.01	5.25	4.94	3.90	2.57	1.12	5.27	.3	
<i>D2S2249</i>	223.10	218.54	∞	4.18	4.51	4.30	3.46	2.34	1.06	4.54	.04	
<i>D2S2359</i>	225.60	220.77	∞	-1.16	.49	1.05	1.18	.85	.40	1.18	.2	
<i>D2S126</i>	228.80	221.84	∞	-1.75	1.26	2.13	2.26	1.65	.77	2.26	.2	
<i>D2S396</i>	240.20	230.51	∞	-6.20	-2.25	-.79	.20	.32	.12	.32	.3	



sequence variants are observed in control individuals in a homozygous state and are not considered pathogenic.

PIP5K3 Molecular Organization

A schematic diagram of the *PIP5K3* protein structure is shown in figure 4A. Homology to several structural fragments from the PDB was found. First, homology to a zinc finger–containing phosphoinositide kinase (FYVE [PDB: 1dvp]) is located at positions 150–219 (E value = $5.9e-18$), with eight cysteines, at positions 160, 164, 167, 180, 183, 188, 191, and 192, that are potentially able to coordinate two zinc atoms. Second, a structural motif shows similarity to a DEP domain (Disheveled, EGL-10, plextrin homology domains of ~70 aa that are present in numerous signaling proteins [PDB: 1fsh]) of unknown function found in secreted proteins (positions 365–440; E value = $8.3e-27$). A search with Superfamily 1.65 localizes a cytosolic chaperone CCT γ apical domain–like motif (PDB: 1gml) at position 677 through 843 of the *PIP5K3* protein (E value = $1.3e-27$), with a sequence identity of 29.8% and a similarity of 58.5%. The 1791–2085 region of the last C-terminal fragment is similar to that of the common kinase core found in the type II β phosphatidylinositol-4-phosphate 5-kinase (PDB: 1bo1) (Rao et al. 1998). The location of these four motifs agrees with that published previously (Shishева et al. 2001). In addition, a small β -sheet “winged helix” DNA/RNA-binding motif at positions 348–489 (E value = $3.8e-18$) and two spectrin repeats at positions 1490–1538 and 1679–1729 were found. Spectrin repeats form a three-helix bundle (PDB: 1quu) and are found in several proteins involved in cytoskeletal structure.

A search using the SMART method shows homology to the archaeal chaperonin thermosome structure (PDB: 1a6d), with an E value of $7.0e-14$. The sequence of this protein is 36% identical to the CCT γ apical domain (Ditzel et al. 1998), containing ~170 overlapping residues. ClustalW 1.74 sequence alignment of the thermosome 1a6d and *PIP5K3* (residues 462–1026) sequences have shown 20.2% identity and 50% similarity, suggesting that the structure of thermosome is suitable for use as a template for building an atomic model of this sequence fragment. The model of the three-dimensional structure of the domain similar to Cpn60-TCP1

was obtained using the thermosome 1a6d structure, as shown in figure 4B.

CFD nonsense mutations interrupt the *PIP4K3* protein sequence at positions 705, 711, 951, 988, 1030, 1038, and 1217. All these mutations affect the C-terminal part of the *PIP5K3* sequence, eliminating both the spectrin repeats and the PIPKc sequence. In addition, the two mutations at positions 705 and 711 remove almost half of the C-terminal domain (fig. 4C), destroying the polar surface of the central cavity of the protein domain possibly involved in protein folding (Ditzel et al. 1998), and are predicted to eliminate the chaperone-like domain of the protein.

Discussion

The CFD locus has been mapped in five unrelated families of European origin to a 24-cM (18-Mb) region of chromosome 2q35 flanked by *D2S2289* and *D2S126*, and CFD has been associated with mutations in *PIP5K3*, a protein which is important for post-Golgi vesicle processing. Mutations were identified in 8 of 10 families in the present study. All but one of these are protein-truncating mutations, predicted to cause termination of the peptide chain before the *PIP5K3* structure is formed and to result in loss of activity.

No mutation was identified in family 50002 or 50006. Affected individuals in both of these families have typical CFD and could not be differentiated clinically from affected individuals from other families in the study. Although family 50006 is small and was not included in the linkage study, family 50002 is linked to the *PIP5K3* region, with a LOD score of 1.74, which is consistent with involvement of *PIP5K3* or a nearby gene, although unaffected individual 3 also inherited the risk haplotype specific for this family. This suggests, but does not prove, that affected individuals in family 50002 may have an intronic or noncoding regulatory mutation that has not yet been identified. Although these will be further investigated as additional families are studied, identification of noncoding mutations can be difficult and may require functional studies of splicing or promoter activity.

A K1103R missense mutation was observed in family 50010. Since most mutations reported here are nonsense mutations, the causative role of this variant may

Figure 4 Schematic diagram of *PIP5K3*, showing the locations and effect of the dominant mutations. *A*, Domain structure of *PIP5K3*. FYVE represents the FYVE zinc-finger domain; DEP represents the Disheveled, EGL-10, plextrin homology domain; Cpn60-TCP1 represents the chaperone-like Cpn-60-TCP1 domain; SPEC represents the two spectrin repeats; and PIPKc represents the domain with phosphatidylinositol-4-phosphate 5-kinase activity. Red arrows show the positions of the truncation mutations associated with CFD, and the blue arrow shows the missense mutation K1103R. *B*, Molecular structure of the Cpn60-TCP1 domain of *PIP5K3*, as predicted by homology modeling with the thermosome structure (PDB: 1a6d) as a structural template. The α helices (cylinders) and β strands (ribbons) are shown. *C*, Effect of dominant mutations in position 711 or 705 on the structure of the Cpn60-TCP1 domain.

be questionable. Several lines of evidence suggest that K1103R is a mutation. This variant segregated in all affected individuals and was not observed in >400 control chromosomes. A search of dbSNP indicated a total of 15 SNPs in the coding region of *PIP5K3*, 8 of which are nonsynonymous. Position 1103 is not among them. In addition, K1103 is conserved in various species as divergent as mouse, *Xenopus*, and *Fugu*. Confirmation of the causative role of this mutation awaits functional assays or studies of additional families with the same base change.

PIP5K3, a large gene comprising 41 exons that span >89 kb, encodes a predicted 2,098-aa protein. The *PIP5K3* protein is a member of the phosphoinositide 3-kinase family, which comprises dual-specificity enzymes possessing an intrinsic protein kinase activity inseparable from a lipid kinase activity. These can generate and relay protein phosphorylation signals to regulate the formation and intracellular location of lipid products (Sbrissa et al. 2000). Both maintenance of mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve (Ikononov et al. 2001; Shisheva et al. 2001). Cultured mammalian cells transiently transfected with a kinase-deficient point mutant, PIKfyve K1831E, show dilation of PIKfyve-containing vesicles and progressive accumulation of multiple swollen lucent endosomal vacuoles, initially in the perinuclear cytoplasm and later in the cell periphery. This indicates that active PIKfyve enzyme must be present in a distinct set of late endocytic membranes for normal cell morphology (Ikononov et al. 2001). The formation of enormously dilated late endocytic structures upon transfection of enzymatically inactive PIKfyve suggests a role for *PIP5K3* in the endosome-to-*trans*-Golgi network (Ikononov et al. 2003b).

It has been suggested that *PIP5K3* selectively regulates the sorting and traffic of peripheral endosomes containing lysosomally directed fluid phase cargo by controlling the morphogenesis and function of multivesicular bodies (Ikononov et al. 2003a). This role is entirely consistent with the clinical and histological findings for CFD, in which the corneal flecks appear to be abnormally swollen keratocytes with membrane-limited intracytoplasmic vacuoles containing complex lipids and glycosaminoglycans (Nicholson et al. 1977). Although the clinical findings for CFD are confined to the cornea, only limited studies of other tissues have been done, and the presence of a subset of abnormal cells in most tissues might not result in clinical symptoms.

In summary, the present study describes both the mapping of the CFD locus in 10 unrelated families of European origin to a 24-cM (18-Mb) region of chromosome 2q35 flanked by *D2S2289* and *D2S126* and the association of CFD with mutations in the *PIP5K3*

protein, which is important for post-Golgi vesicle processing. Mutations were identified in 8 of 10 families studied. All but one of these mutations are predicted to result in truncation of the *PIP5K3* protein before the protein structure is formed, resulting in the loss of activity. Enzymatic studies of the *PIP5K3* enzyme in affected individuals should further elucidate the role of this enzyme in CFD and in normal cellular metabolism.

Acknowledgments

We thank the members of the families, for their participation in this study, and Céline Agosti, Tatiana Favez, and Sylviane Métrailler, for their technical assistance. We acknowledge support from the Swiss National Science Foundation (grant 32-065250.01).

Web Resources

The accession number and URLs for data presented herein are as follows:

GCG-Lite+ ClustalW 1.74 multiple sequence alignment program, <http://www.ebi.ac.uk/clustalw/>
 NCBI, <http://www.ncbi.nlm.nih.gov/> (for reference genomic sequence [accession number NM_015040])
 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for CFD)
 PFAM, <http://www.sanger.ac.uk/Software/Pfam/>
 ScanProsite, tool to search the PROSITE database, <http://us.expasy.org/tools/scanprosite/>
 RADAR, <http://www.ebi.ac.uk/Radar/>
 SMART at European Laboratory of Molecular Biology, <http://smart.embl-heidelberg.de/>
 Superfamily 1.65, HMM library and genome assignment service, <http://supfam.mrc-lmb.cam.ac.uk/>

References

- Abola E, Bernstein FC, Bryant SH, Koetzle TF, Weng J (1987) Protein data bank. In: Allen FH, Bergerhoff G, Sievers R (eds) Crystallographic databases—information content, software systems, scientific applications. Data Commission of the International Union of Crystallography, Cambridge, United Kingdom, pp 107–132
- Akova YA, Unlu N, Duman S (1994) Fleck dystrophy of the cornea: a report of cases from three generations of a family. *Eur J Ophthalmol* 4:123–125
- Birndorf LA, Ginsberg SP (1972) Hereditary fleck dystrophy associated with decreased corneal sensitivity. *Am J Ophthalmol* 73:670–672
- Cottingham RW, Idury RM, Schaffer AA (1993) Faster sequential genetic linkage computations. *Am J Hum Genet* 53:252–263
- Ditzel L, Lowe J, Stock D, Stetter KO, Huber H, Huber R, Steinbacher S (1998) Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT. *Cell* 93:125–138
- François J, Neetens A (1957) Nouvelle dystrophie hérédofam-

- iliale du parenchyme corneen (hérédodystrophie mouchetée). *Bull Soc Belge Ophthalmol* 114:641–646
- Frueh BE, Bohnke M (1999) In vivo confocal microscopy of fleck dystrophy. *Cornea* 18:658–660
- Goldberg MF, Krimmer B, Sugar J, Sewell J, Wong P (1977) Variable expression in flecked (speckled) dystrophy of the cornea. *Ann Ophthalmol* 9:889–896
- Ikonomov OC, Sbrissa D, Foti M, Carpentier JL, Shisheva A (2003a) PIKfyve controls fluid phase endocytosis but not recycling/degradation of endocytosed receptors or sorting of procathepsin D by regulating multivesicular body morphogenesis. *Mol Biol Cell* 14:4581–4591
- Ikonomov OC, Sbrissa D, Mlak K, Deeb R, Fligger J, Soans A, Finley RL Jr, Shisheva A (2003b) Active PIKfyve associates with and promotes the membrane attachment of the late endosome-to-*trans*-Golgi network transport factor Rab9 effector p40. *J Biol Chem* 278:50863–50871
- Ikonomov OC, Sbrissa D, Shisheva A (2001) Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve. *J Biol Chem* 276:26141–26147
- Jiao X, Munier FL, Schorderet DF, Zografos L, Smith J, Rubin B, Hejtmancik JF (2003) Genetic linkage of Francois-Neetens fleck (mouchetée) corneal dystrophy to chromosome 2q35. *Hum Genet* 112:593–599
- Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl Cryst* 26:283–291
- Lathrop GM, Lalouel JM (1984) Easy calculations of lod scores and genetic risks on small computers. *Am J Hum Genet* 36:460–465
- Lee C (1994) Predicting protein mutant energetics by self-consistent ensemble optimization. *J Mol Biol* 236:918–939
- Lee C, Subbiah S (1991) Prediction of protein side-chain conformation by packing optimization. *J Mol Biol* 217:373–388
- Needleman SB, Wunsch CD (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J Mol Biol* 48:443–453
- Nicholson DH, Green WR, Cross HE, Kenyon KR, Massof D (1977) A clinical and histopathological study of Francois-Neetens speckled corneal dystrophy. *Am J Ophthalmol* 83:554–560
- Patten JT, Hyndiuk RA, Donaldson DD, Herman SJ, Ostler HB (1976) Fleck (mouchetee) dystrophy of the cornea. *Ann Ophthalmol* 8:25–32
- Purcell JJ Jr, Krachmer JH, Weingeist TA (1977) Fleck corneal dystrophy. *Arch Ophthalmol* 95:440–444
- Rao VD, Misra S, Boronenkov IV, Anderson RA, Hurley JH (1998) Structure of type II^β phosphatidylinositol phosphate kinase: a protein kinase fold flattened for interfacial phosphorylation. *Cell* 94:829–839
- Sbrissa D, Ikonomov OC, Shisheva A (2000) PIKfyve lipid kinase is a protein kinase: downregulation of 5'-phosphoinositide product formation by autophosphorylation. *Biochemistry* 39:15980–15989
- Schaffer AA, Gupta SK, Shriram K, Cottingham RW (1994) Avoiding recomputation in genetic linkage analysis. *Hum Hered* 44:225–237
- Shisheva A, Rusin B, Ikonomov OC, DeMarco C, Sbrissa D (2001) Localization and insulin-regulated relocation of phosphoinositide 5-kinase PIKfyve in 3T3-L1 adipocytes. *J Biol Chem* 276:11859–11869
- Smith RJH, Holcomb JD, Daiger SP, Caskey CT, Pelias MZ, Alford BR, Fontenot DD, Hejtmancik JF (1989) Exclusion of Usher syndrome gene from much of chromosome 4. *Cytogenet Cell Genet* 50:102–106
- Streeten BW, Falls HF (1961) Hereditary fleck dystrophy of the cornea. *Am J Ophthalmol* 51:275–281